SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Quoin Pharmaceuticals
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Quoin Pharmaceuticals, Ltd.'s American Depositary Shares.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Quoin Pharmaceuticals, Ltd.
- The filing indicates that the Reporting Persons beneficially own an aggregate of 1,081,183 American Depositary Shares of Quoin Pharmaceuticals, Ltd.
- This ownership represents 4.99% of the class of securities, which are American Depositary Shares, each representing one Ordinary Share.
- Armistice Capital, LLC is identified as an investment adviser (IA) and Steven Boyd as a parent holding company/control person (HC) and individual (IN).
- The shares are held with shared voting power and shared dispositive power for both Armistice Capital, LLC and Steven Boyd.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a factual disclosure of beneficial ownership, not a performance report or strategic announcement. The filing explicitly states the investment is passive and not for control purposes.
Positives
- The filing indicates a passive investment, meaning the Reporting Persons do not intend to influence or change the control of Quoin Pharmaceuticals, Ltd., which can provide stability for current management and strategic direction.
- The investment is stated to be held in the ordinary course of business, suggesting a standard portfolio allocation rather than an aggressive activist stance.
Risks
- The document explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, mitigating immediate control-related risks from this specific filing.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Quoin Pharmaceuticals, Ltd.'s future performance or strategic direction, as it is solely an ownership disclosure.
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm and an individual in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive investor's stake, potentially offering some stability given the non-activist nature of the filing.
- Management: The explicit statement that the investment is not for the purpose of changing or influencing control suggests no immediate threat of activist intervention from these Reporting Persons.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 05/15/2025 | Date of signing the Schedule 13G Amendment No. 1 |
Keywords
Quoin Pharmaceuticals, QNRX, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Passive Investment, American Depositary Shares, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.